Enabling you to identify and mitigate the intrinsic risk in your operations, supply chains and business processes.
Evaluating how your products and services meet and exceed quality, safety, sustainability and performance standards.
Validating the specifications, value and safety of your raw materials, products and assets.
GMP clinical batch release of oligonucleotides requires identity testing by a combination of two or more analytical procedures to overcome inherent specificity limitations of individual procedures. This case study from Intertek's Dr Jo-Anne Riley, provides a snapshot of how high resolution accurate mass with tandem mass spectrometry provides oligonucleotide identity confirmation by intact accurate mass measurement and sequence confirmation.